These findings indicate a possible mechanism in which FGF16 may prevent cardiac hypertrophy and fibrosis by competing with FGF2 for the binding site of FGFR1c (Table 1) (Matsumoto et al., 2013). This evidence concerns the gene FGF16 and cardiac hypertrophy.